Invivyd, Inc. (NASDAQ:IVVD) Receives Average Recommendation of “Hold” from Brokerages

Invivyd, Inc. (NASDAQ:IVVD) has been given an average recommendation of “Hold” by the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $8.00.

IVVD has been the subject of several research reports. Weiss Ratings lowered Invivyd from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. BTIG Research restated a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. HC Wainwright reiterated a “buy” rating on shares of Invivyd in a report on Tuesday, August 18th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Invivyd in a report on Thursday.

Insider Activity

In related news, insider Jill Andersen sold 37,256 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $0.72, for a total value of $26,824.32. Following the completion of the transaction, the insider directly owned 314,480 shares in the company, valued at $226,425.60. This trade represents a 10.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 228,024 shares of company stock valued at $176,540. 12.25% of the stock is owned by company insiders.

Institutional Investors Weigh In On Invivyd

Hedge funds have recently bought and sold shares of the business. Chicago Partners Investment Group LLC purchased a new stake in Invivyd in the first quarter worth about $25,000. Bronte Capital Management Pty Ltd. purchased a new position in shares of Invivyd during the fourth quarter valued at approximately $27,000. DRW Securities LLC purchased a new position in shares of Invivyd during the fourth quarter valued at approximately $27,000. ProShare Advisors LLC bought a new stake in shares of Invivyd in the 4th quarter worth approximately $30,000. Finally, State of Wyoming bought a new stake in shares of Invivyd in the 4th quarter worth approximately $30,000. Institutional investors own 70.36% of the company’s stock.

Invivyd Price Performance

Shares of NASDAQ IVVD opened at $0.90 on Friday. Invivyd has a 1 year low of $0.53 and a 1 year high of $3.07. The stock has a market capitalization of $265.31 million, a P/E ratio of -2.73 and a beta of 0.71. The company’s 50-day moving average is $0.78 and its 200 day moving average is $1.19.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The company had revenue of $14.29 million during the quarter, compared to analysts’ expectations of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. Research analysts anticipate that Invivyd will post -0.51 earnings per share for the current year.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.